Does the media refer more to CAPR or ADMA?

In the previous week, Capricor Therapeutics had 48 more articles in the media than ADMA Biologics. MarketBeat recorded 51 mentions for Capricor Therapeutics and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.33 beat Capricor Therapeutics' score of 0.05 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CAPR or VCEL?

In the previous week, Capricor Therapeutics had 49 more articles in the media than Vericel. MarketBeat recorded 51 mentions for Capricor Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Capricor Therapeutics' score of 0.05 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AGIO or CAPR?

In the previous week, Capricor Therapeutics had 40 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 51 mentions for Capricor Therapeutics and 11 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.94 beat Capricor Therapeutics' score of 0.05 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Is CAPR or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% Mesoblast N/A N/A N/A

Does the media refer more to CAPR or MESO?

In the previous week, Capricor Therapeutics had 50 more articles in the media than Mesoblast. MarketBeat recorded 51 mentions for Capricor Therapeutics and 1 mentions for Mesoblast. Capricor Therapeutics' average media sentiment score of 0.05 beat Mesoblast's score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer STOK or CAPR?

In the previous week, Capricor Therapeutics had 50 more articles in the media than Stoke Therapeutics. MarketBeat recorded 51 mentions for Capricor Therapeutics and 1 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.38 beat Capricor Therapeutics' score of 0.05 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Capricor Therapeutics (CAPR) Competitors

$9.07 -0.35 (-3.72%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$9.16 +0.09 (+0.99%)

As of 09/18/2026 07:59 PM Eastern

Compare

CAPR vs. ADMA, VCEL, AGIO, MESO, and STOK

Should you buy Capricor Therapeutics stock or one of its competitors? Capricor Therapeutics's main competitors and comparable companies include ADMA Biologics (ADMA), Vericel (VCEL), Agios Pharmaceuticals (AGIO), Mesoblast (MESO), and Stoke Therapeutics (STOK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Capricor Therapeutics compare to ADMA Biologics?

Capricor Therapeutics (NASDAQ:CAPR) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Capricor Therapeutics had 48 more articles in the media than ADMA Biologics. MarketBeat recorded 51 mentions for Capricor Therapeutics and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.33 beat Capricor Therapeutics' score of 0.05 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ADMA Biologics has a net margin of 32.98% compared to Capricor Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
ADMA Biologics	32.98%	40.17%	26.97%

ADMA Biologics has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	23.68	-$105.04M	-$2.45	N/A
ADMA Biologics	$510.17M	4.00	$146.93M	$0.70	13.01

Capricor Therapeutics currently has a consensus price target of $30.25, suggesting a potential upside of 233.52%. ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 104.90%. Given Capricor Therapeutics' higher possible upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Capricor Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

ADMA Biologics beats Capricor Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Capricor Therapeutics compare to Vericel?

Capricor Therapeutics (NASDAQ:CAPR) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Capricor Therapeutics had 49 more articles in the media than Vericel. MarketBeat recorded 51 mentions for Capricor Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Capricor Therapeutics' score of 0.05 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vericel has a net margin of 7.91% compared to Capricor Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Vericel	7.91%	6.91%	5.02%

Vericel has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	23.68	-$105.04M	-$2.45	N/A
Vericel	$276.26M	7.42	$16.52M	$0.47	85.15

Capricor Therapeutics presently has a consensus price target of $30.25, indicating a potential upside of 233.52%. Vericel has a consensus price target of $58.40, indicating a potential upside of 45.93%. Given Capricor Therapeutics' higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Capricor Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Vericel has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Summary

Vericel beats Capricor Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Capricor Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Agios Pharmaceuticals presently has a consensus target price of $41.25, indicating a potential upside of 24.74%. Capricor Therapeutics has a consensus target price of $30.25, indicating a potential upside of 233.52%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Capricor Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	36.54	-$412.78M	-$7.01	N/A
Capricor Therapeutics	$22.27M	23.68	-$105.04M	-$2.45	N/A

In the previous week, Capricor Therapeutics had 40 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 51 mentions for Capricor Therapeutics and 11 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.94 beat Capricor Therapeutics' score of 0.05 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

21.7% of Capricor Therapeutics shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Capricor Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Capricor Therapeutics	N/A	-56.60%	-43.97%

Agios Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Summary

Capricor Therapeutics beats Agios Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Capricor Therapeutics compare to Mesoblast?

Capricor Therapeutics (NASDAQ:CAPR) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Capricor Therapeutics had 50 more articles in the media than Mesoblast. MarketBeat recorded 51 mentions for Capricor Therapeutics and 1 mentions for Mesoblast. Capricor Therapeutics' average media sentiment score of 0.05 beat Mesoblast's score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Capricor Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

Mesoblast's return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Mesoblast	N/A	N/A	N/A

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Capricor Therapeutics presently has a consensus target price of $30.25, suggesting a potential upside of 233.52%. Mesoblast has a consensus target price of $39.00, suggesting a potential upside of 157.77%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Capricor Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mesoblast has higher revenue and earnings than Capricor Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	23.68	-$105.04M	-$2.45	N/A
Mesoblast	$120.25M	16.34	-$57.50M	-$0.28	N/A

Summary

Capricor Therapeutics beats Mesoblast on 8 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Capricor Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Capricor Therapeutics' return on equity of -56.60% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Capricor Therapeutics	N/A	-56.60%	-43.97%

Stoke Therapeutics presently has a consensus target price of $44.25, indicating a potential upside of 55.65%. Capricor Therapeutics has a consensus target price of $30.25, indicating a potential upside of 233.52%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Capricor Therapeutics had 50 more articles in the media than Stoke Therapeutics. MarketBeat recorded 51 mentions for Capricor Therapeutics and 1 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.38 beat Capricor Therapeutics' score of 0.05 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Stoke Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Stoke Therapeutics has higher revenue and earnings than Capricor Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$3.34	N/A
Capricor Therapeutics	$22.27M	23.68	-$105.04M	-$2.45	N/A

Summary

Capricor Therapeutics beats Stoke Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPR vs. The Competition

Export

Metric	Capricor Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$526.74M	$3.89B	$7.25B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-3.70	8.10	210.29	20.60
Price / Sales	23.68	1,456.59	656.37	93.45
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	1.64	15.47	10.50	6.32
Net Income	-$105.04M	-$22.90M	$3.49B	$358.20M
7 Day Performance	8.36%	-1.21%	0.59%	1.12%
1 Month Performance	32.60%	-3.29%	-1.74%	-2.39%
1 Year Performance	36.39%	37.74%	18.13%	5.35%

Capricor Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPR Capricor Therapeutics	2.8397 of 5 stars	$9.07 -3.7%	$30.25 +233.5%	+36.4%	$526.74M	$22.27M	N/A	231	Trending News Analyst Forecast
ADMA ADMA Biologics	3.0075 of 5 stars	$8.61 -5.8%	$18.67 +116.8%	-42.7%	$2.05B	$510.17M	12.30	647	Positive News
VCEL Vericel	3.7237 of 5 stars	$39.72 +0.3%	$58.40 +47.0%	+26.3%	$2.03B	$276.26M	84.51	398	Positive News
AGIO Agios Pharmaceuticals	3.3497 of 5 stars	$32.81 -1.2%	$41.25 +25.7%	-12.3%	$1.98B	$98.34M	N/A	540	Trending News Analyst Revision
MESO Mesoblast	1.4696 of 5 stars	$14.74 -1.9%	$39.00 +164.6%	-11.1%	$1.95B	$120.25M	N/A	108

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPR) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Competitors

CAPR vs. ADMA, VCEL, AGIO, MESO, and STOK

How does Capricor Therapeutics compare to ADMA Biologics?

Summary

How does Capricor Therapeutics compare to Vericel?

Summary

How does Capricor Therapeutics compare to Agios Pharmaceuticals?

Summary

How does Capricor Therapeutics compare to Mesoblast?

Summary

How does Capricor Therapeutics compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Competitors

CAPR vs. ADMA, VCEL, AGIO, MESO, and STOK

How does Capricor Therapeutics compare to ADMA Biologics?

Does the media refer more to CAPR or ADMA?

Do institutionals and insiders hold more shares of CAPR or ADMA?

Is CAPR or ADMA more profitable?

Which has stronger valuation and earnings, CAPR or ADMA?

Do analysts recommend CAPR or ADMA?

Which has more volatility and risk, CAPR or ADMA?

Summary

How does Capricor Therapeutics compare to Vericel?

Does the media prefer CAPR or VCEL?

Do insiders & institutionals believe in CAPR or VCEL?

Is CAPR or VCEL more profitable?

Which has higher valuation and earnings, CAPR or VCEL?

Do analysts prefer CAPR or VCEL?

Which has more volatility & risk, CAPR or VCEL?

Summary

How does Capricor Therapeutics compare to Agios Pharmaceuticals?

Do analysts recommend AGIO or CAPR?

Which has higher earnings & valuation, AGIO or CAPR?

Does the media favor AGIO or CAPR?

Do insiders & institutionals have more ownership in AGIO or CAPR?

Is AGIO or CAPR more profitable?

Which has more volatility and risk, AGIO or CAPR?

Summary

How does Capricor Therapeutics compare to Mesoblast?

Does the media refer more to CAPR or MESO?

Which has more risk and volatility, CAPR or MESO?

Is CAPR or MESO more profitable?

Do insiders & institutionals hold more shares of CAPR or MESO?

Do analysts recommend CAPR or MESO?

Which has better valuation & earnings, CAPR or MESO?

Summary

How does Capricor Therapeutics compare to Stoke Therapeutics?

Is STOK or CAPR more profitable?

Do analysts rate STOK or CAPR?

Do insiders & institutionals believe in STOK or CAPR?

Does the media prefer STOK or CAPR?

Which has more volatility and risk, STOK or CAPR?

Which has preferable valuation & earnings, STOK or CAPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools